<DOC>
	<DOC>NCT02050360</DOC>
	<brief_summary>The purpose of this study is to determine whether "on-demand" sildenafil is effective in the treatment of Raynaud's phenomenon.</brief_summary>
	<brief_title>"As Required" Oral Sildenafil in Raynaud's Phenomenon</brief_title>
	<detailed_description />
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Active Raynaud's Phenomenon characterized by a clinical history of primary or secondary Raynaud's Phenomenon At least 7 RP attacks per week on 5 or more days per week (assessed over the 2 weeks preceding inclusion) Patients who have dated and signed the informed consent form Contraception for women Recently diagnosed RP (less than 2 months). Uncontrolled hypertension, diabetes mellitus, angina Haemodynamic instability Nonarteritic ischemic optic neuropathy Pulmonary hypertension Subjects currently taking sildenafil, tadalafil or vardenafil Subjects currently taking nitrates Subjects currently taking strong CYP3A inhibitors Pregnancy (or considering pregnancy in the next 4 months) Breast feeding Participation in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Raynaud's phenomenon</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>Local cooling</keyword>
	<keyword>Microcirculation</keyword>
</DOC>